Arcus Biosciences, Inc. (RCUS)
29.21
-1.38
(-4.51%)
USD |
NYSE |
Aug 28, 16:00
29.18
-0.03
(-0.10%)
After-Hours: 20:00
Arcus Biosciences Profit Margin (Quarterly) : -222.0% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -222.0% |
| March 31, 2026 | -752.9% |
| December 31, 2025 | -321.2% |
| September 30, 2025 | -519.2% |
| June 30, 2025 | 0.00% |
| March 31, 2025 | -400.0% |
| December 31, 2024 | -361.5% |
| September 30, 2024 | -191.7% |
| June 30, 2024 | -238.5% |
| March 31, 2024 | -2.76% |
| December 31, 2023 | -261.3% |
| September 30, 2023 | -221.9% |
| June 30, 2023 | -258.6% |
| March 31, 2023 | -320.0% |
| December 31, 2022 | -200.4% |
| September 30, 2022 | -193.3% |
| June 30, 2022 | -249.0% |
| March 31, 2022 | -377.6% |
| Date | Value |
|---|---|
| December 31, 2021 | 78.81% |
| September 30, 2021 | -824.2% |
| June 30, 2021 | -803.0% |
| March 31, 2021 | -767.3% |
| December 31, 2020 | -546.6% |
| September 30, 2020 | 2.82% |
| June 30, 2020 | -2.58K% |
| March 31, 2020 | -1.59K% |
| December 31, 2019 | -170.2% |
| September 30, 2019 | -1.28K% |
| June 30, 2019 | -1.61K% |
| March 31, 2019 | -1.01K% |
| December 31, 2018 | -787.1% |
| September 30, 2018 | -252.0% |
| June 30, 2018 | -1.08K% |
| March 31, 2018 | -1.04K% |
| December 31, 2017 | -1.06K% |
| September 30, 2017 | -14.19K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 47.80% |
| AVITA Medical, Inc. | -35.31% |
| Iovance Biotherapeutics, Inc. | -47.64% |
| Editas Medicine, Inc. | -153.3% |
| Recursion Pharmaceuticals, Inc. | -1.71K% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -88.33% |
| Return on Assets | -41.56% |
| Return on Invested Capital | -70.79% |
| Gross Profit Margin (Quarterly) | 95.12% |
| Operating Margin (Quarterly) | -234.1% |
| Return on Net Operating Assets | -688.6% |